Clinical evaluation of a new functional test for detection of plasma procoagulant phospholipids

Abstract

The objective of this study was to validate a simple factor Xa-based clotting test developed to monitor procoagulant phospholipids (PPLs) and platelet-derived microparticles (PMPs). This assay is easily automated, giving it a major advantage over the more laborious and expensive flow cytometry, electron microscopy and ELISA techniques in general usage at present. The intra-assay and inter-assay variation coefficients were less than 5% at both low and high levels of PPLs. The test is not affected by other clotting factors is assured by the use of a phospholipid-free animal plasma, which provides excess factor V, fibrinogen and prothrombin. This test was evaluated in apparently healthy volunteers and in selected patient groups associated with increased levels of PMPs in the circulation (diabetes mellitus, sickle cell disease, thyroid cancer and patients with multiple trauma). The study showed that XaCT has a high discriminating power for PPLs and that the patient groups have significantly highly increased PPLs activities when compared with healthy volunteers. Although of a preliminary nature, the test has shown that it has the sensitivity for discriminating severity of disease, as it could detect patients in sickle cell crisis and differentiate between type 1 and 2 diabetes. In conclusion, the combination of reliability, reproducibility and easy performance makes the XaCT assay a simple test to screen for PPLs in plasma samples.

Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women

“…The assay measures the clotting time in a system dependent on the total plasma phase procoagulant phospholipid content of the sample [26]. It differs from solid phase assays in that there is no pre-selection of annexin-V bound activity.…”

Cell-Derived Microparticles in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis

“…1, 713 records were identified, and 48 studies involving 2,460 patients with type 2 diabetes and 1,880 non-diabetic controls were included in the systematic review . Among them, data from 34 reports were meta-analyzed since the others [12,14,20,23,24,29,30,33,34,37,39,40,46,58] did not provide available data for pooling the interested outcomes. Among the reports for qualitative analyses only, results of TMPs [26], PMPs [12, 20, 28-30, 33, 34, 39, 40, 58] and MMPs [26,29,32,40] were controversial, while the results of LMPs [39,58] and EMPs [14,20,23,24,26,29,37,39,40,58] were consistent with each other.…”

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2

“…The STA-Procoag-PPL assay (Diagnostica Stago), evaluating the procoagulant activity of phospholipid microparticles, 20 was then performed. Briefly, 25 mL of test plasma was mixed with 25 mL of phospholipid-depleted human plasma and prewarmed for 2 minutes at 37°C.…”